Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$49.33BQ3 2026+1.3%
Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.
$21.04B2025+4.0%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. One bar per fiscal year, as filed. Stops at the last completed year.
$16.73BQ3 2026-2.8%33.9% of revenue
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
33.9%Q3 2026-4.0%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.
$8.72B2025-20.1%
Cash left over after running and maintaining the business. One bar per fiscal year, as filed. Stops at the last completed year.
$3.402025+1.8%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. One bar per fiscal year, as filed. Stops at the last completed year.
4.45B2025-0.3%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. One point per fiscal year, as filed. Stops at the last completed year.
14.9x2025-50.6%
14.9x today · median 30.1x and range 13.3x–53.9x across the points shown, 2020 to 2025
Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.
$7.65B2025+17.3%
Cash handed to shareholders. A flat line at zero means the company pays none. One bar per fiscal year, as filed. Stops at the last completed year.
Everything above comes from Novo Nordisk A/S’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted. This company files in DKK. Figures are converted to US dollars at $1.00 = 6.7640 DKK, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s.
Share-count jumps we cannot explain: 1.97x around Dec 31, 2021. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Total Operating Expenses, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Impairments, Depreciation, Change in Payables and Accruals, Change in Customer Advances, Change in Other Operating Capital, Change in Working Capital, Accounts Payable, Acquisitions, and Shares Issued for Cash. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
$41.64+2.4%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 4, 2026
Novo Nordisk sells prescription medicines for diabetes and obesity to patients and the health systems, insurers and pharmacies that pay for them.